Elsevier

Molecular and Cellular Endocrinology

Volume 458, 15 December 2017, Pages 82-90
Molecular and Cellular Endocrinology

Therapeutic applications of thyroid hormone analogues in resistance to thyroid hormone (RTH) syndromes

https://doi.org/10.1016/j.mce.2017.02.029Get rights and content

Highlights

  • Thyroid hormone analogs hold therapeutic potential in resistance to thyroid hormone (RTH) syndromes.

  • In a subset of RTH-β patients, Triac effectively alleviates of thyrotoxic symptoms.

  • DITPA partially restored peripheral thyrotoxicosis in MCT8 deficiency in preclinical and clinical studies.

  • Triac exerts benefical effects in animal models for AHDS.

Abstract

Thyroid hormone (TH) is crucial for normal development and metabolism of virtually all tissues. TH signaling is predominantly mediated through binding of the bioactive hormone 3,3′,5-triiodothyronine (T3) to the nuclear T3-receptors (TRs). The intracellular TH levels are importantly regulated by transporter proteins that facilitate the transport of TH across the cell membrane and by the three deiodinating enzymes. Defects at the level of the TRs, deiodinases and transporter proteins result in resistance to thyroid hormone (RTH) syndromes. Compounds with thyromimetic potency but with different (bio)chemical properties compared to T3 may hold therapeutic potential in these syndromes by bypassing defective transporters or binding to mutant TRs. Such TH analogues have the potential to rescue TH signaling. This review describes the role of TH analogues in the treatment of RTH syndromes. In particular, the application of 3,3′,5-triiodothyroacetic acid (Triac) in RTH due to defective TRβ and the role of 3,5-diiodothyropropionic acid (DITPA), 3,3′,5,5’-tetraiodothyroacetic acid (Tetrac) and Triac in MCT8 deficiency will be highlighted.

Introduction

Thyroid hormone (TH) is crucial for normal development and metabolism of virtually all tissues. Its important developmental role is best illustrated by the severe consequences of untreated congenital hypothyroidism which results in growth impairment and intellectual disability (Grüters and Krude, 2012). The thyroid gland mainly produces the inactive prohormone thyroxine (T4) and to a lesser extent the bioactive hormone 3,3′,5-triiodothyronine (T3). The main effects of TH are exerted through binding of T3 to its nuclear receptor (thyroid hormone receptor, TR), which functions as a ligand-dependent transcription factor. The main receptor isoforms are TRα1 and 2 and TRβ1 and 2, which differ in their tissue distribution (Cheng et al., 2010). TRα1 and TRβ1 and 2 are bona fide T3-interacting receptors. The amount of T3 available for receptor binding is importantly determined by the intracellular deiodinases (DIO1-3), which facilitate the activation of T4 to T3 (DIO1 and DIO2) and/or the inactivation of T4 to 3,3′,5’-triiodothyronine (rT3) and of T3 to 3,3’-diiodothyronine (3,3′-T2; DIO1 and DIO3). In addition, decarboxylation of the alanine side-chain, resulting in the formation of iodothyronamines, and subsequent oxidative deamination, resulting in the formation of iodothyroacetic acids, comprise another mechanism of iodothyronine metabolism (Wood et al., 2009, Hoefig et al., 2016). Importantly, some of these metabolic intermediates have been found to exert biological effects, of which the thyromimetic effects of 3,3′,5-triiodothyroacetic acid (Triac) have been most extensively studied (Groeneweg et al., 2017 submitted). The transport of TH across the plasma membrane by membrane transporter proteins is another crucial step that governs intracellular TH concentrations (Hennemann et al., 2001). Many transporters have been shown to facilitate TH transport, of which the monocarboxylate transporter (MCT)8 is the most specific TH transporter identified to date (reviewed in Visser, 2007; Bernal et al., 2015, Kinne et al., 2010). Thus, cellular TH action requires adequate function of (1) TH transporter proteins, (2) deiodinases and (3) nuclear receptors.

Defects in any of these processes give rise to distinct clinical syndromes, collectively called disorders of TH signaling or resistance to thyroid hormone (RTH) syndromes (Refetoff et al., 2014, Dumitrescu and Refetoff, 2013). So far, clinical phenotypes have been associated with mutations in TRβ (reviewed in Dumitrescu and Refetoff, 2013), TRα (Bochukova et al., 2012, Van Mullem et al., 2012) and MCT8 (Friesema et al., 2004, Dumitrescu et al., 2004). No mutations in deiodinases have been identified yet, although mutations in SECIS-binding protein 2 (SBP2) and selenocysteine transfer RNA, both required for the adequate production of deiodinases and other selenoproteins, have been reported (reviewed in Fu and Dumitrescu, 2014, Schoenmakers et al., 2016).

Compounds with thyromimetic potency but with different (bio)chemical properties compared to T3 may hold therapeutic potential in RTH syndromes by bypassing defective transporters or binding to mutant TRs. The application of bioactive TH metabolites or synthetic TH analogues has been studied in many different contexts (e.g. heart failure or primary hypothyroidism). This review will focus on the (putative) application of these compounds in the treatment of RTH syndromes.

Section snippets

Properties of TH analogues used in RTH syndromes

The TH analogues studied in the context of RTH syndromes (RTH-β and MCT8 deficiency) are 3,3′,5-triiodothyroacetic acid (Triac), 3,3′,5,5’-tetraiodothyroacetic acid (Tetrac),3,5-diiodothyropropionic acid (DITPA) and dextro(D)-T4 (choloxin). Tetrac and Triac are naturally occurring metabolites of TH in humans, although present at ∼50-fold lower concentrations than T4 and T3, respectively (Crossley and Ramsden, 1979, Gavin et al., 1980, Menegay et al., 1989). Their major serum binding protein is

Background and rationale of TH analogue therapy

Heterozygous mutations of TRβ are the common genetic cause of RTHβ (Weiss et al., 2016). So far, over 3000 cases have been identified and about 132 distinct pathogenic mutations have been identified in the TRβ gene (Weiss et al., 2016). These mutations generally cluster within three distinct hot spots (Fig. 1). Mutant receptors exhibit a diminished T3 binding affinity and/or impaired interaction with co-regulators involved in the mediation of T3 action and generally display a dominant negative

TH analogues and RTHα

Mutations in the TRα isoform have been recently identified (Bochukova et al., 2012, Van Mullem et al., 2012). The resulting phenotype has been coined RTHα, predominantly characterized by abnormal bone development, constipation, anemia and various degrees of neurocognitive impairments (Moran and Chatterjee, 2015). These clinical features are accompanied by subtle changes in thyroid parameters, including low-normal serum (F)T4 and high-normal serum (F)T3 concentrations in the context of normal

Background and rationale of TH analogue therapy

The only TH transporter that is currently linked to clinical disease is MCT8 (Friesema et al., 2004, Dumitrescu et al., 2004). Mutations in MCT8 result in AHDS, characterized by severe intellectual disability and abnormal serum thyroid function tests (TFTs), including elevated serum T3, reduced rT3 and low or low-normal (F)T4 levels in the presence of a normal to high-normal TSH. MCT8 has been found to be essential for TH transport across the blood-brain-barrier (BBB) and into neuronal cells (

TH analogues and defects of deiodination

Mutations in SBP2 and selenocysteine transfer RNA disturb deiodination of TH and several of its metabolites and produce a typical biochemical thyroid fingerprint (elevated serum T4 and rT3 and low to low-normal T3 levels in the presence of normal or slightly elevated TSH levels). However, it is unclear which features, if any, can be attributed to defective TH signaling. Several reports mention beneficial effects of L-T3 treatment on body height (Di Cosmo et al., 2009b, Azevedo et al., 2010,

Concluding remark

The thyromimetic action and hence applicability of TH analogues is importantly determined by their receptor isoform specificity, tissue availability and metabolic clearance. These analogue specific properties largely determine their applicability in the treatment of RTHβ syndromes. In humans, Triac has a role in the treatment of RTHβ, in particular for patients harboring mutations in clusters 1 or 2 of TRβ. Advancing insight into the protein structure of the TR isoforms and substrate-receptor

Conflict of interest

The authors declare that they have no conflicts of interest.

All authors have nothing to disclose.

Acknowledgments

This work was supported by a grant from the Netherlands Organisation for Health Research and Development (project number 113303005) (to WEV) and from the Sherman Foundation (to WEV).

References (112)

  • K.R. Latham et al.

    Development of support matrices for affinity chromatography of thyroid hormone receptors

    J. Biol. Chem.

    (1981)
  • N. Messier et al.

    Triac regulation of transcription is T(3) receptor isoform- and response element-specific

    Mol. Cell. Endocrinol.

    (2000)
  • N. Messier et al.

    In vitro effect of Triac on resistance to thyroid hormone receptor mutants: potential basis for therapy

    Mol. Cell. Endocrinol.

    (2001)
  • C. Moran et al.

    Resistance to thyroid hormone due to defective thyroid receptor alpha

    Best. Pract. Res. Clin. Endocrinol. Metab.

    (2015)
  • B. Sjouke et al.

    Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

    Lancet Diabetes Endocrinol.

    (2014)
  • R.C. Smallridge et al.

    Thyroid hormone resistance in a large kindred: physiologic, biochemical, pharmacologic, and neuropsychologic studies

    Am. J. Med.

    (1989)
  • W.R. Trotter

    Effect of triiodothyroacetic acid on blood-cholesterol levels

    Lancet

    (1956)
  • M. Aguilar Diosdado et al.

    Hyperthyroidism due to familial pituitary resistance to thyroid hormone: successful control with 3, 5, 3' triiodothyroacetic associated to propranolol

    J. Endocrinol. Invest

    (1991)
  • R. Anzai et al.

    Long-term 3,5,3'-triiodothyroacetic acid therapy in a child with hyperthyroidism caused by thyroid hormone resistance: pharmacological study and therapeutic recommendations

    Thyroid

    (2012)
  • C. Asteria et al.

    Prenatal diagnosis of thyroid hormone resistance

    J. Clin. Endocrinol. Metab.

    (1999)
  • M.F. Azevedo et al.

    Selenoprotein-related disease in a young girl caused by nonsense mutations in the SBP2 gene

    J. Clin. Endocrinol. Metab.

    (2010)
  • S. Bárez-López et al.

    Effect of triiodothyroacetic acid treatment in Mct8 deficiency: a word of caution

    Thyroid

    (2016)
  • P. Beck-Peccoz et al.

    Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3’-triiodothyroacetic acid (TRIAC)

    J. Endocrinol. Invest

    (1983)
  • P. Beck-Peccoz et al.

    Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST

    J. Clin. Endocrinol. Metab.

    (1990)
  • J. Bernal et al.

    Thyroid hormone transporters-functions and clinical implications

    Nat. Rev. Endocrinol.

    (2015)
  • E. Bochukova et al.

    A mutation in the thyroid hormone receptor alpha gene

    N. Engl. J. Med.

    (2012)
  • G. Brenta et al.

    Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid

    J. Clin. Endocrinol. Metab.

    (2003)
  • L.D. Brun et al.

    Effects of dextrothyroxine on the pituitary-thyroid axis in hypercholesterolemic children and goitrous adults

    J. Clin. Endocrinol. Metab.

    (1980)
  • A. Ceballos et al.

    Importance of monocarboxylate transporter 8 for the blood-brain barrier-dependent availability of 3,5,3'-triiodo-L-thyronine

    Endocrinology

    (2009)
  • A. Chatzitomaris et al.

    A novel de novo mutation in the thyroid hormone receptor-beta gene

    Exp. Clin. Endocrinol. Diabetes

    (2015)
  • S.Y. Cheng et al.

    Molecular aspects of thyroid hormones actions

    Endocr. Rev.

    (2010)
  • R.J. Clifton-Bligh et al.

    A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation

    Mol. Endocrinol.

    (1998)
  • D. Cortelazzi et al.

    Maternal compound W serial measurements for the management of fetal hypothyroidism

    Eur. J. Endocrinol.

    (1999)
  • A. Crinò et al.

    Antiiodothyronine autoantibodies in a girl with hyperthyroidism due to pituitary resistance to thyroid hormones

    J. Endocrinol. Invest

    (1992)
  • F. Darendeliler et al.

    Successful therapy with 3,5,3¢- triiodothyroacetic acid (TRIAC) in pituitary resistance to thyroid hormone

    J. Pediatr. Endocrinol. Metab.

    (1997)
  • J. Delbaere et al.

    MCT8 deficiency in Purkinje cells disrupts embryonic chicken cerebellar development

    J. Endocrinol.

    (2017)
  • C. Di Cosmo et al.

    A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport

    Endocrinology

    (2009)
  • C. Di Cosmo et al.

    Clinical and molecular characterization of a novel selenocysteine insertion sequence-binding protein 2 (SBP2) gene mutation (R128X)

    J. Clin. Endocrinol. Metab.

    (2009)
  • F. Dorey et al.

    Thyrotoxicosis due to pituitary resistance to thyroid hormones. Successful control with D thyroxine: a study in three patients

    Clin. Endocrinol. (Oxf)

    (1990)
  • A.J. Dulgeroff et al.

    Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone

    J. Clin. Endocrinol. Metab.

    (1992)
  • A.M. Dumitrescu et al.

    Mutations in SECISBP2 result in abnormal thyroid hormone metabolism

    Nat. Genet.

    (2005)
  • A.M. Dumitrescu et al.

    Tissue specific thyroid hormone deprivation and excess in Mct8 deficient mice

    Endocrinology

    (2006)
  • G. Faglia et al.

    Inappropriate secretion of thyrotropin by the pituitary

    Horm. Res.

    (1987)
  • A.M. Ferrara et al.

    Placenta passage of the thyroid hormone analog DITPA to male wild-type and Mct8-deficient mice

    Endocrinology

    (2014)
  • A.M. Ferrara et al.

    The thyroid hormone analog DITPA ameliorates metabolic parameters of male mice with Mct8 deficiency

    Endocrinology

    (2015)
  • D. Forrest et al.

    Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function

    EMBO J.

    (1996)
  • L.A. Gavin et al.

    Serum concentration, metabolic clearance, and production rates of 3,5,3'-triiodothyroacetic acid in normal and athyreotic man

    J. Clin. Endocrinol. Metab.

    (1980)
  • B. Gloss et al.

    Different configurations of specific thyroid hormone response elements mediate opposite effects of thyroid hormone and GC-1 on gene expression

    Endocrinology

    (2005)
  • S. Goldman et al.

    DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure. Phase II Trial Veterans Affairs Cooperative Study

    Circulation

    (2009)
  • C.A. Gorman et al.

    Comparative effectiveness of dextrothyroxine and levothyroxine in correcting hypothyroidism and lowering blood lipid levels in hypothyroid patients

    J. Clin. Endocrinol. Metab.

    (1979)
  • Cited by (0)

    View full text